sj-pdf-1-mso-10.1177_2055217320972137 - Supplemental material for Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Supplemental material, sj-pdf-1-mso-10.1177_2055217320972137 for Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years by Dana Horáková, Aaron Boster, Antonio Bertolotto, Mark S Freedman, Isabel Firmino*, Steven J Cavalier, Alan K Jacobs*, Karthinathan Thangavelu*, Nadia Daizadeh, Elizabeth M Poole*, Darren P Baker, David H Margolin*, Tjalf Ziemssen and on behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 Investigators in Multiple Sclerosis Journal—Experimental, Translational and Clinical